Aims: To investigate the effects of a newly developed color-coded educational glucose control instruction (COLOR), combined with a color-displayed glucose meter on changes in type-2 diabetes patient’s behavior and th...Aims: To investigate the effects of a newly developed color-coded educational glucose control instruction (COLOR), combined with a color-displayed glucose meter on changes in type-2 diabetes patient’s behavior and their HbA1c levels. Material and Methods: Patients using a COLOR-self-monitoring of blood glucose (SMBG) method were instructed to record daily blood glucose levels with red (high glucose ≥ 180 mg/dL) or blue (low glucose ≤ 70 mg/dL) colored circles on their SMBG notebooks according to the colors displayed on the glucose meter. Results: COLOR-SMBG showed an improved the actual behavior modification scores by 14% compared to Conventional group at 1-month follow-up展开更多
Background: The purpose of this study was to evaluate the effects of sitagliptin in elderly patients with type 2 diabetes aged 75 years or older versus those aged 65 - 74 years. Methods: Outpatients aged 65 years or o...Background: The purpose of this study was to evaluate the effects of sitagliptin in elderly patients with type 2 diabetes aged 75 years or older versus those aged 65 - 74 years. Methods: Outpatients aged 65 years or older with type 2 diabetes who received sitagliptin at a dose of 50 mg daily for 6 months were divided into two groups: those who were 75 years and older and those who were 65 - 74 years. The efficacy and safety were retrospectively evaluated by comparison of laboratory values before and after the administration of sitagliptin and by review of adverse events after treatment. Results: One hundred and twelve older patients with type 2 diabetes were studied. Six months after the initiation of sitagliptin, participants’ hemoglobin A1c was significantly decreased by 1.09% ± 0.8% in 65 - 74-year-olds (66 patients;mean age, 69.1 ± 3.0 years;mean HbA1c before administration, 8.4% ± 0.8%) and by 1.05% ± 0.8% in patients 75 years or older (46 patients;mean age, 79.8 ± 4.1 years;mean HbA1c before administration, 8.5% ± 0.7%). There was no significant difference in hemoglobin A1c between the two groups. Furthermore, sitagliptin was well tolerated in both age groups. Conclusions: In elderly patients (75 years or older) with type 2 diabetes, the effect of sitagliptin was similar that in older patients (younger than 75 years) with type 2 diabetes.展开更多
文摘Aims: To investigate the effects of a newly developed color-coded educational glucose control instruction (COLOR), combined with a color-displayed glucose meter on changes in type-2 diabetes patient’s behavior and their HbA1c levels. Material and Methods: Patients using a COLOR-self-monitoring of blood glucose (SMBG) method were instructed to record daily blood glucose levels with red (high glucose ≥ 180 mg/dL) or blue (low glucose ≤ 70 mg/dL) colored circles on their SMBG notebooks according to the colors displayed on the glucose meter. Results: COLOR-SMBG showed an improved the actual behavior modification scores by 14% compared to Conventional group at 1-month follow-up
文摘Background: The purpose of this study was to evaluate the effects of sitagliptin in elderly patients with type 2 diabetes aged 75 years or older versus those aged 65 - 74 years. Methods: Outpatients aged 65 years or older with type 2 diabetes who received sitagliptin at a dose of 50 mg daily for 6 months were divided into two groups: those who were 75 years and older and those who were 65 - 74 years. The efficacy and safety were retrospectively evaluated by comparison of laboratory values before and after the administration of sitagliptin and by review of adverse events after treatment. Results: One hundred and twelve older patients with type 2 diabetes were studied. Six months after the initiation of sitagliptin, participants’ hemoglobin A1c was significantly decreased by 1.09% ± 0.8% in 65 - 74-year-olds (66 patients;mean age, 69.1 ± 3.0 years;mean HbA1c before administration, 8.4% ± 0.8%) and by 1.05% ± 0.8% in patients 75 years or older (46 patients;mean age, 79.8 ± 4.1 years;mean HbA1c before administration, 8.5% ± 0.7%). There was no significant difference in hemoglobin A1c between the two groups. Furthermore, sitagliptin was well tolerated in both age groups. Conclusions: In elderly patients (75 years or older) with type 2 diabetes, the effect of sitagliptin was similar that in older patients (younger than 75 years) with type 2 diabetes.
